Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBI-1076986
- Development stage
- Phase 1
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NBI-1076986 is an investigational, orally administered small molecule that acts as a selective antagonist of the muscarinic acetylcholine receptor M4 (M4 receptor). It was discovered and is being developed by Neurocrine Biosciences for the potential treatment of movement disorders. The drug specifically targets the M4 subtype among muscarinic receptors, which are implicated in motor coordination and certain central nervous system pathologies. As of June 2025, it is in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults[1][2][3][4][5][7][8][9][10].
02
Targets
CHRM4 (M4)
Beyond the preview
Go deeper on NBI-1076986.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBI-1076986.